SOFINNOVA PARTNERS SAS purchased 5.7% of their position (220K shares) of CINCOR PHARMA, INC. on the open market
Open‑market purchase worth $3.52M — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 1/13/2022ACC: 0001209191-22-003195
10% Owner
Since Jan 2022
-9.06M
Net shares
Net seller
$3.52M
Total acquired
1
Open market trades
1B · 0S
4
Total transactions
4.09M acquired · 13.15M disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+3.87M
Price / share
—
Trade value
—
% of position
New position
1/11/2022
0.00→3.87M
Common Stock
Indirect
Shares
+220K
Price / share
$16.00
Trade value
$3.52M
% of position
5.7%
1/11/2022
3.87M→4.09M
Total
Net shares
+4.09M
Net value
$3.52M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 1/11/2022 | C · Conversion | +3.87M | — | — | New position | 0.00 | 3.87M |
| Common Stock Indirect | 1/11/2022 | P · Purchase | +220K | $16.00 | $3.52M | 5.7% | 3.87M | 4.09M |
| Total | +4.09M | $3.52M | ||||||
Derivative Transactions2
Series A Preferred Stock
Indirect
Converts to
Common Stock
2.94M shares
Shares
−10M
Strike price
Held after
0.00
Exercisable
—
1/11/2022
Series B Preferred Stock
Indirect
Converts to
Common Stock
926.47K shares
Shares
−3.15M
Strike price
Held after
0.00
Exercisable
—
1/11/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A Preferred Stock Indirect | Common Stock2.94M shares | 1/11/2022 | C · Conversion | −10M | — | 0.00 | |
| Series B Preferred Stock Indirect | Common Stock926.47K shares | 1/11/2022 | C · Conversion | −3.15M | — | 0.00 |